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ABSTRACT Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality
and resource use worldwide. The goal of this official American Thoracic Society (ATS)/European
Respiratory Society (ERS) Research Statement is to describe evidence related to diagnosis, assessment, and
management; identify gaps in knowledge; and make recommendations for future research. It is not
intended to provide clinical practice recommendations on COPD diagnosis and management.
Clinicians, researchers and patient advocates with expertise in COPD were invited to participate. A
literature search of Medline was performed, and studies deemed relevant were selected. The search was not
a systematic review of the evidence. Existing evidence was appraised and summarised, and then salient
knowledge gaps were identified.
Recommendations for research that addresses important gaps in the evidence in all areas of COPD were
formulated via discussion and consensus.
Great strides have been made in the diagnosis, assessment and management of COPD, as well as
understanding its pathogenesis. Despite this, many important questions remain unanswered. This ATS/
ERS research statement highlights the types of research that leading clinicians, researchers and patient
advocates believe will have the greatest impact on patient-centred outcomes.
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Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality. Given the
10-year interval since publication of the official American Thoracic Society (ATS)/European Respiratory
Society (ERS) standards for the diagnosis and treatment of patients with COPD [1], leaders of the societies
felt a need to summarise evidence related to the diagnosis, assessment, and management of COPD;
identify knowledge gaps and research questions; and make recommendations for future research. This
research statement is not intended to be a clinical practice guideline; other documents are available that
provide clinical recommendations for stable COPD [2, 3], and a forthcoming ATS/ERS document will
provide clinical recommendations related to COPD exacerbations.
Methods
The methods used to develop this research statement are described in the full-length version of the
document, found at www.atsjournals.org and www.erj.ersjournals.com
Definitions
COPD
The ATS and ERS define COPD as a preventable and treatable disease state characterised by airflow
limitation that is not fully reversible [1]. The airflow limitation is usually progressive and associated with a
chronic inflammatory response of the lungs to noxious particles or gases. Cigarette smoking is the most
common risk factor [4], but others are increasingly being recognised (e.g. biomass fuels and α1-antitrypsin
deficiency). Dyspnoea and exacerbations are the most prominent respiratory manifestations of COPD. In
most patients, COPD represents the pulmonary component of a chronic multimorbidity.
Outcomes
Outcomes are the results of an intervention. Traditionally, many outcomes measured in COPD research
have been physiological, such as lung function (e.g. forced expiratory volume in 1 s (FEV1)) or functional
capacity (e.g. 6-min walking distance). Physiological outcomes are desirable because they are readily
measured, provide information about disease progression, and are related to clinical outcomes such as
mortality and exacerbations. Anatomical outcomes have also been used in studies of COPD, such as
histological or imaging findings. Physiological and anatomical outcomes make research easier, more
efficient and less costly.
There is increasing recognition, however, that the relationship between many surrogate outcomes (i.e.
physiological and/or anatomical outcomes) and outcomes that matter to patients (i.e. “patient-centred” or
“patient-important” outcomes, such as dyspnoea, quality of life, frequency of exacerbations, frequency of
hospitalisations and mortality) is modest at best, and interventions that improve surrogate outcomes
frequently do not affect patient-centred outcomes. As a result, there is increasing emphasis on: 1) using
patient-centred outcomes in clinical research; and 2) finding high-quality surrogate outcomes that reliably
predict patient-centred outcomes [5].
We recommend:
• Studies that determine which outcomes matter most to patients with COPD and, therefore, are truly
patient-centred outcomes in this population.
• Studies that correlate physiological and anatomical outcomes with patient-centred outcomes, to identify
high-quality surrogate outcomes that may be used in future research.
• Preferential use of patient-centred outcomes to inform judgments related to patient care until surrogate
outcomes have been identified that strongly correlate with patient-centred outcomes.
Clinical manifestations and initial assessment
The diagnosis of COPD is first suspected when a patient: 1) complains of a cough, sputum production,
dyspnoea, or recurrent lower respiratory infections; 2) reports risk factors for the disease, such as exposure
to cigarette smoke or environmental or occupational pollutants; or 3) presents with an acute exacerbation.
The physical examination is performed to identify respiratory and systemic effects of COPD. A normal
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physical examination is common in mild COPD, with signs (e.g. quiet breath sounds, a prolonged
expiratory duration and weight loss) becoming apparent as the disease progresses.
Chest radiography is generally performed during the initial diagnostic evaluation of patients with suspected
COPD to exclude other diseases that may cause similar symptoms and signs and to establish the presence of
concomitant respiratory diseases. It is frequently normal in early COPD. Computed tomography (CT) can
estimate the degree of emphysema and its distribution and identify bronchial wall thickening and gas trapping.
These estimates correlate with lung function abnormalities, but there are substantial variations among those
interpreting the studies [6, 7]. To mitigate interpreter variability, numerous quantitative techniques have been
applied [8, 9]. For many reasons, however, these techniques have not become routine clinical practice [10–13].
Additional advantages of CT scanning are that it can help differentiate between structural abnormalities
that cause airflow limitation (e.g. emphysema, bronchiolitis and bronchiectasis), identify abnormalities that
are associated with clinically significant features (i.e. phenotypes), and detect both pulmonary
comorbidities (e.g. lung cancer, interstitial lung disease and pulmonary hypertension) and nonpulmonary
comorbidities (e.g. coronary artery calcifications, heart failure and diseases of the mediastinum) [14].
We recommend:
• Studies to determine whether there is a role for routine CT scanning among patients with newly
diagnosed COPD.
• Studies to identify CT findings that reliably and consistently correlate airway dimension measurements
with lung function, using pulmonary function tests as the reference standard.
• Studies to identify CT findings that are associated with clinically significant features (i.e. phenotypes)
and differential responses to treatment.
• Studies to determine the optimal CT protocol and quantification methods. The results may allow CT
scans performed using different types of CT scanners to be compared with one another, which would
facilitate longitudinal assessment, multicentre trials, and multicentre clinical care.
Diagnosis
Diagnosis of COPD requires confirmation of an airflow limitation that is not fully reversible via spirometry
in a patient who has a history of a potentially causative exposure (e.g. smoking). Airflow limitation that is
not fully reversible is defined by a low post-bronchodilator FEV1/forced vital capacity (FVC) ratio [1].
The threshold FEV1/FVC ratio that should be used to confirm an airflow limitation is uncertain. A
post-bronchodilator FEV1/FVC ratio of <0.7 has traditionally been the criterion for airflow limitation [1].
However, this threshold may result in more frequent identification of airflow limitation and, hence, more
frequent diagnosis of COPD among the elderly [15] and less frequent diagnosis among young adults
<45 years of age [16] compared with a threshold based on the lower limit of normal (LLN) of FEV1/FVC.
Advocates for the fixed ratio argue that it identifies a number of patients with significant pulmonary
pathology and respiratory morbidity not detected by the LLN [17], and advocates for the LLN argue that
the fixed ratio is more likely to yield false-positive results [15].
Screening asymptomatic individuals for COPD using spirometry is controversial. There is evidence that
screening detects undiagnosed COPD [18]. However, asymptomatic individuals with mild airflow
limitation (Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade 1) may not have faster
lung function decline or a lower quality of life than asymptomatic individuals with normal lung function
[19], and there are no data showing that outcomes improve among individuals who are identified as
having COPD before developing symptoms, that early treatment provides any benefit in asymptomatic
individuals, or that screening is cost effective [20].
We recommend:
• Studies that measure the accuracy of various tools (e.g. questionnaires) to detect symptoms in patients at
risk for COPD, using spirometry as the reference standard.
• Studies that compare outcomes among individuals diagnosed with COPD on the basis of an FEV1/FVC
ratio <0.70 with those among individuals diagnosed with COPD on the basis of an FEV1/FVC below the
LLN.
• Studies that compare outcomes among symptomatic individuals whose COPD diagnosis is based on the
combination of an airflow limitation confirmed by spirometry and a history of exposure to the causative
agent with those among symptomatic individuals whose COPD diagnosis has not been confirmed with
spirometry but rather is based on an alternative approach. Examples of alternative approaches include
various combinations of symptoms, imaging findings, and physiological abnormalities measured by
complementary tests such as forced oscillation techniques.
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• Studies that evaluate case-finding strategies using questionnaires, mini-spirometers and office spirometry
in areas where access to conventional spirometry requires specialised assessment.
• Studies that examine the impact of ascertainment (e.g. by spirometric screening versus spirometry performed
due to symptoms and an exposure history) on medium- and long-term outcomes in individuals with COPD.
• Studies that evaluate the impact of age on the importance of identifying an airflow limitation (i.e. is it
more important to identify asymptomatic airflow limitation in a 30 year old than an 80 year old?).
Assessment after diagnosis
Disease severity
The severity of a disease relates to the extent of functional impairment of the target organ(s). Classification
of COPD severity by spirometry alone (table 1) predicts patient-centred outcomes, such as health status
[21], use of healthcare resources [22], frequency of exacerbations [23, 24], and mortality [25]. Body mass
index (BMI) and functional dyspnoea (i.e. dyspnoea that affects functional ability, employment, quality of
life or health status [26] also predict patient-centred outcomes. BMI is obtained by dividing the weight (in
kg) by the height (in m2); values <21 kg·m−2 are associated with increased mortality [27, 28]. The severity
of functional dyspnoea can be assessed using the modified Medical Research Council (mMRC) dyspnoea
score (table 2) [29]. Increased functional dyspnoea is associated with increased mortality [30].
Several composite indices of disease severity have been developed (table 3) [31–37]. Although the
prognostic accuracy of each of these indices has been confirmed in separate studies, few studies have
directly compared one index to another.
The GOLD Global Strategy for the Diagnosis, Management, and Prevention of COPD [2] proposed a
multidimensional assessment of COPD for the purposes of treatment selection. The assessment includes:
1) high/low symptoms using the mMRC dyspnoea scores, the COPD Assessment Test or the clinical
COPD questionnaire; 2) the severity of airflow limitation; and 3) the number of yearly exacerbations.
Patients with high symptoms (mMRC dyspnoea score ⩾2, COPD Assessment Test score ⩾10 or clinical
COPD questionnaire ⩾1) and GOLD grade 3 or 4 spirometry and/or frequent exacerbations (two or more
exacerbations in the preceding year and/or one hospitalisation) are considered at high risk for further
exacerbations and, indirectly, poor clinical outcomes.
Concomitant chronic diseases may greatly contribute to the severity of disease in patients with COPD, and
inclusion of comorbidities in the multidimensional evaluation of patients with COPD is useful in the
context of comprehensively evaluating patients with COPD [38, 39].
TABLE 2 Modified Medical Research Council Dyspnoea Scale
Grade Description
0 Not troubled with breathlessness, except during strenuous exercise
1 Troubled by shortness of breath when hurrying or walking up a slight hill
2 Walks slower than people of the same age due to breathlessness or has to stop for breath
when walking at own pace on a level surface
3 Stops for breath after walking about 100 m or after a few minutes on a level surface
4 Too breathless to leave the house or breathless when dressing or undressing
TABLE 1 Spirometric classification of chronic obstructive pulmonary disease (COPD)
Severity of obstruction Post-bronchodilator FEV1/FVC FEV1 % predicted
At risk >0.7 ⩾80
Mild COPD ⩽0.7 ⩾80
Moderate COPD ⩽0.7 50–80
Severe COPD ⩽0.7 30–50
Very severe COPD ⩽0.7 <30
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity. At risk are patients who: smoke or have
exposure to pollutants; have cough, sputum or dyspnoea; and have a family history of chronic respiratory
disease.
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We recommend:
• Studies that determine which index or indices best stratify patients for the purpose of determining
disease severity or recommending treatment.
• Studies that determine if short-term changes in these indices or other measures (e.g. lung function, CT
findings and biomarkers) are useful surrogate markers of medium- or long-term patient-centred
outcomes, thus shortening the time needed to complete therapeutic trials.
• Studies that contribute to a better understanding of the pathogenesis, impact, prevention and treatment
of concomitant diseases in patients with COPD.
Disease activity
Activity of a disease relates to the level of activation of the biological processes that drive disease
progression. The biological processes that drive disease progression in COPD are likely to be related to the
balance between the pulmonary and systemic inflammatory responses to inhalational injury and the
subsequent repair process [40]. In theory, identifying and treating active pathological processes may
mitigate or eliminate disease progression.
It is unclear how to measure disease activity. Potential surrogate markers include the rate of change of
clinical markers of disease progression, because faster rates of disease progression presumably indicate
more disease activity. Examples of clinical markers of disease progression include worsening dyspnoea and
health status, loss of exercise capacity, cough and sputum production, active smoking, appearance or
worsening of comorbidities, weight loss and frequency of exacerbations [41, 42]. Other measures can be
categorised as functional markers (e.g. FEV1 decline, deterioration of the diffusing capacity of the lung for
carbon monoxide and progressive hyperinflation), structural markers (e.g. progression of emphysema,
worsening of airway dimensions and appearance or worsening of bronchiectasis), and biological markers
(e.g. biological markers in the lung, circulating blood, exhaled air and/or urine).
We recommend:
• Studies that relate potential biomarkers of disease activity (e.g. rate of lung function decline, increased
exacerbation frequency, inflammation, lung tissue destruction and repair responses induced by
inhalational injury) to patient-centred outcomes to validate the biomarkers as clinically useful measures
of disease activity.
• Studies that evaluate the impact of disease activity on treatment response and, conversely, the effects of
treatment on disease activity.
Phenotyping
A phenotype is the observable properties of an organism, which are determined by its genotype and modulated
by its environment [43]. A clinical COPD phenotype has been defined as “A single or combination of disease
attributes that describe differences between individuals with COPD as they relate to clinically meaningful
outcomes (e.g. symptoms, exacerbations, response to therapy, rate of disease progression or death)” [44].
Clinical phenotyping may be complicated for several reasons. First, the presentation of some clinical
phenotypes may change due to either the effect of therapy and/or the natural course of the disease.
TABLE 3 Composite prognostic indexes in chronic obstructive pulmonary disease
Composite index Components [Ref.]
BODE BMI, FEV1, mMRC dyspnoea scale and 6MWD [31]
mBODE BMI, FEV1, mMRC dyspnoea scale and V´O
2
peak [32]
eBODE BMI, FEV1, mMRC dyspnoea scale, 6MWD and exacerbation rate [33]
BODEx BMI, FEV1, mMRC dyspnoea scale and exacerbation rate [34]
Inflammatory BODE BODE, inflammatory biomarkers, age and hospitalisation history [35]
ADO Age, mMRC dyspnoea scale and FEV1 [36]
DOSE mMRC dyspnoea scale, FEV1, smoking status and exacerbation rate [37]
CODEx Comorbidity, obstruction, dyspnoea and previous severe exacerbations [39]
BODE: body mass index (BMI), airflow obstruction, dyspnoea, exercise capacity; mBODE: modified BODE in
which 6MWD is replaced by peak oxygen consumption; eBODE: exacerbations added to the original BODE;
BODEx: exacerbations replace 6MWD in the original BODE; inflammatory BODE: inflammatory markers added
to the original BODE; ADO: age, dyspnoea and airflow obstruction index; DOSE: dyspnoea, airflow obstruction,
smoking status and exacerbations index; CODEx: comorbidities, airflow obstruction, dyspnoea and
exacerbations index;. FEV1: forced expiratory volume in 1 s (severity of airflow obstruction); mMRC: modified
Medical Research Council; 6MWD: 6-min walking distance; V´O
2
peak: peak oxygen consumption.
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Secondly, although a COPD phenotype describes differences between individuals with COPD, a given
patient can have more than one clinical phenotype. Finally, two prevalent diseases can coexist (e.g. COPD
and obstructive sleep apnoea, or COPD and asthma).
Only a few COPD phenotypes have been validated. They include α1-antitrypsin deficiency, frequent (two
or more per year) exacerbations, chronic bronchitis and upper lobe emphysema with poor exercise
tolerance after rehabilitation in patients with severe airflow limitation. Other COPD phenotypes have been
proposed but still require validation confirming their relationship with clinically meaningful outcomes:
severe hypoxaemia, disproportionate symptoms, persistent systemic inflammation, chronic airway bacterial
colonisation, emphysema predominance with pulmonary hyperinflation and lung cancer, the asthma/
COPD overlap syndrome, premature or early severe airflow limitation (<55 years), out-of-proportion
pulmonary hypertension (mean pulmonary arterial pressure >40 mmHg), COPD in never-smokers, and
the four new patient types (i.e. types A, B, C and D) proposed by GOLD [2]. Even if some of these
phenotypes are associated with clinically meaningful outcomes, many experts believe that research should
focus on those phenotypes where outcomes can be modified with therapy. In fact, exploratory therapeutic
interventions in targeted populations are recommended for the validation of a clinical phenotype.
We recommend:
• Studies to relate potential phenotypic traits with outcomes. Such evidence may provide more
individualised prognostic information.
• Studies to relate potential phenotypic traits with response to therapy. Such evidence may identify
specific types of patients who are more or less likely to respond to a given therapy, facilitate the
development of personalised medicine, and increase the priority of future research studies that plan to
enrol phenotypes whose outcomes can be potentially modified by therapy.
• Studies to enhance understanding of the treatment impact of various COPD phenotypes (e.g. asthma/
COPD overlap, α1-antitrypsin deficiency, bronchiectasis, etc.).
Comorbidities
COPD is frequently associated with one or more comorbidities and/or systemic effects. Therefore, in many
patients it can be considered just the pulmonary component of the multimorbidity that is characterised by
concomitant chronic diseases (e.g. hypertension, atherosclerosis, chronic heart failure, lung cancer,
osteoporosis, depression, etc.) and systemic effects (e.g. weight loss and muscle weakness) that are not fully
explained by ageing and other common risk factors (e.g. smoking, diet, inactivity, lifestyle, etc.) [45–47].
Chronic comorbidities are prominent contributors to the clinical severity of patients with COPD, as they
often affect important patient-centred outcomes.
Ischaemic heart disease is a common comorbidity, contributing to worsening health and functional status
[48], increased risk of a longer exacerbation [48], more dyspnoea [48], and decreased survival [49]. COPD is
also associated with an increased incidence of lung cancer [50, 51] and prevalence of diabetes, hypertension
and other cardiovascular diseases, even after controlling for tobacco smoking in some studies. Evidence
supports the clustering of certain comorbidities with COPD [52], thereby suggesting potential common
pathobiological pathways for these diseases. There is also increasing evidence that acute exacerbations of
respiratory symptoms in patients with COPD may be caused by extrapulmonary mechanisms and
exacerbations of concomitant chronic diseases, such as systemic arterial hypertension, acute heart
decompensation, atrial fibrillation and pulmonary embolism [53]. Conversely, COPD exacerbations appear
to impact the risk of cardiovascular events [54]. Although acute exacerbations of respiratory symptoms occur
more frequently in patients with COPD, they also occur with significant frequency in smokers without
COPD, suggesting that they are not specific for COPD [54, 55]. Patients with COPD have a similar
prevalence of sleep apnoea as the general population. When this overlap syndrome exists, patients are treated
with continuous positive airway pressure, because this has been shown to decrease mortality [56].
We recommend:
• Studies to confirm or exclude an association between specific comorbidities and COPD.
• Studies to elucidate pathobiological mechanisms linking COPD to its comorbidities.
• Studies to explore the mechanisms of exacerbations of respiratory symptoms in patients with COPD.
• Studies to determine the nature and optimal therapeutic management of patients with concomitant
chronic diseases, particularly heart failure and/or ischaemic heart disease.
Pathophysiology and pathology
The pathophysiology and pathology of COPD are described in the full-length version of the document,
found at www.atsjournals.org and www.erj.ersjournals.com
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Management
Smoking cessation
Stopping smoking increases life expectancy at any age [57]. Smoking cessation reduces the rate of decline
of lung function in patients with COPD and, therefore, is an important goal of treating smokers with
COPD [58]. It has been hypothesised that objective evidence of disease may motivate smokers to quit.
This was supported by a study that found that communicating the results of spirometry in terms of the
smoker’s “lung age” (i.e. the age at which a healthy individual acquires similar results) improved the
likelihood of smoking cessation [59]. However, other data are conflicting. Two studies found that smokers
whose spirometry identified COPD had higher quit rates than smokers whose spirometry did not identify
COPD [60, 61], whereas another study found that confronting smokers with abnormal spirometry results
did not improve smoking cessation rates [62].
Smokers with COPD appear to be just as responsive as smokers without COPD to pharmacotherapy
directed at smoking cessation. This is supported by the observation that smoking quit rates were similar in
trials that enrolled smokers with mild-to-moderate COPD compared with trials that enrolled general
populations of smokers [63–66]. It is unknown whether these findings apply to patients with severe COPD
because such patients have been scarcely studied. It is likely that some comorbidities affect responsiveness
to smoking cessation interventions and others do not. For example, studies have shown that depression
negatively impacts smoking cessation [67], whereas cardiovascular disease does not [68].
Pharmacological aids for smoking cessation can be allocated into two categories: controllers (e.g. nicotine
patch, bupropion and varenicline), which target long-term abstinence; and relievers (e.g. nicotine gum) for
rapid relief of acute cravings for tobacco or heightened withdrawal symptoms. Generally speaking, the
controller medication is taken on a regular dosing schedule, with the dose and duration determined by the
severity of nicotine dependence and symptoms of withdrawal. The reliever is used on an as-needed basis
to manage acute urges to smoke or breakthrough withdrawal symptoms. Although this strategy is intuitive
and has been anecdotally successful, its outcomes have not been studied in controlled trials.
Pharmacotherapy plus counselling improves smoking cessation compared with either pharmacotherapy or
counselling alone [69, 70]. However, the optimal intensity of counselling is unknown [66, 71].
Electronic cigarettes (i.e. e-cigarettes) are battery-powered devices that, when puffed like a cigarette,
produce vapours that can contain nicotine. This eliminates the inhalation of most of the toxic constituents
of tobacco cigarettes, although the risks of e-cigarettes are incompletely understood. E-cigarettes are
growing in popularity because they have behavioural features similar to those of conventional cigarettes,
yet are presumed to be a less harmful alternative that can decrease both cravings and withdrawal
symptoms. They are being used as either a substitute for conventional cigarettes or as an aid to quitting
smoking [72–74]. Additional research on e-cigarettes has become an urgent need because the presumed
benefits of e-cigarettes are unproven and the long-term risks are unknown, yet e-cigarettes are
commercially available and becoming increasingly popular [75]. In particular, the efficacy of e-cigarettes as
a smoking cessation strategy is unknown. A concern is that individuals who might otherwise avoid regular
cigarette smoking due to fear of adverse health effects might be attracted to presumably safer electronic
cigarettes and thereby become addicted to nicotine. The Forum of International Respiratory Societies,
which includes the ATS and ERS, has published a position statement on e-cigarettes [76].
Patients frequently fail to quit smoking and, therefore, ask whether decreased smoking is sufficient to
derive some benefit. Although one study suggests that smoking reduction improves respiratory symptoms
[77], it is unclear if smoking reduction slows the rate of lung function decline [78–81]. Studies suggest that
smoking reduction is associated with a greater probability of future cessation [81]
Marijuana smoking is now legal in two states within the USA for recreational purposes and for medical
purposes in several others, yet the risk of marijuana smoking on the development of COPD is uncertain.
As an example, multiple studies have found that long-term marijuana smoking is associated with
symptoms of COPD, but an association with fixed airflow obstruction has been inconsistent [82]. The
reasons for the inconsistent findings are not understood.
We recommend:
• Studies comparing the smoking quit rate of individuals who undergo spirometry with the smoking quit
rate of those who do not undergo spirometry, using different techniques to add value to the spirometry
results (e.g. lung age and functional limitation). Among those undergoing spirometry, quit rates should
be compared among those with and without airflow obstruction.
• Studies to clarify the optimal approach to achieve abstinence from smoking. Examples include a
controller plus a reliever versus a controller or reliever alone, various combinations and durations of
pharmacological agents, various intensities of counselling, and add-on therapies if initial therapy fails.
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• Studies that measure the potential benefits (i.e. smoking quit rate, incidence of COPD and incidence of
lung cancer) and harms (i.e. addiction rate, toxicology, carcinogenesis and cost-effectiveness) of
e-cigarettes, both short- and long-term.
• Studies that compare outcomes among patients who have quit smoking, reduced the amount that they
smoke, or continued smoking the same amount.
• Studies investigating the genetic basis of smoking addiction and cessation.
• Studies comparing existing smoking cessation strategies and seeking novel smoking cessation strategies
and drugs.
• Studies to determine whether marijuana smoking increases the incidence of COPD and, if so, to identify
which individuals are at greatest risk.
Standard pharmacological therapies
Lung function is improved and the frequency of acute COPD exacerbations is reduced by long-acting
β-agonists (LABAs), inhaled corticosteroids (ICS), combined LABA/ICS, and long-acting antimuscarinic
antagonists (LAMAs) [83–85]. Health-related quality of life is also improved by ICS, LABAs, LABA/ICS
and LAMAs [83–85]. LABA/ICS and LAMAs may improve mortality in unselected patients with COPD
[83, 84], although the evidence for this effect is limited because the studies had a low event rate due to the
inclusion of patients at low risk for mortality [86]. Finally, the rate of decline of lung function might be
reduced by inhaled medications, but this is only supported by subgroup analyses [87, 88] of randomised
trials [83, 84]. All of these effects are modest, possibly due to differential effects on COPD subtypes.
An as-needed inhaled short-acting β-agonist is generally the first medication initiated, often with a
standing dose of an inhaled long-acting bronchodilator. However, the optimal long-acting bronchodilator
regimen is unknown. In a systematic review of seven randomised trials that directly compared a LAMA
(i.e. tiotropium) with LABAs, meta-analyses found that the LAMA had a greater effect on reducing
COPD exacerbations, exacerbation-related hospitalisations and adverse effects, but there were no
differences in mortality, all-cause hospitalisations, symptoms or lung function [89]. The meta-analyses
were limited by heterogeneity, suggesting that the differences between the LAMA and LABAs may have
been due to the specific LABA (i.e. salmeterol, formoterol or indacaterol), the population studied or
genetic predisposition [90]. In other words, whereas the LAMA was superior to the LABAs collectively,
the possibility that one of the LABAs is superior to the LAMA in some subgroups or the entire COPD
population cannot be excluded. The meta-analyses evaluated only the 12-h LABAs because they preceded
the introduction of 24-h acting LABAs; however, a subsequent direct comparison between the LAMA
tiotropium and the 24-h LABA indacaterol confirmed the superiority of LAMAs in reducing
exacerbations [91].
The LABA/ICS combination is sometimes added instead of an inhaled long-acting bronchodilator. The
combination improves health-related quality of life and reduces the risk of a moderate or severe COPD
exacerbation when compared with placebo, LABA alone or ICS alone [83]. The combination also reduces
the rate of lung function decline when compared with placebo but not when compared with a LABA alone
or ICS alone [83]. The LABA/ICS combination may have a modest effect on overall mortality [83]. The
primary adverse effect attributed to the LABA/ICS combination is an increased risk of pneumonia,
although this effect may not be present to the same degree with all formulations of a LABA/ICS [92, 93].
The LABA/ICS combination was equivalent to the LAMA in terms of exacerbation prevention in the only
direct comparison with a LAMA [94]. Several other outcomes (i.e. health status and mortality) favoured
the LABA/ICS combination over the LAMA, but confidence in these results is limited by the small
number of events [94]. Adding a LAMA to the LABA/ICS combination appears to reduce the rate of
severe exacerbations and improve symptoms in patients with moderate or severe COPD [95].
LABA/LAMA combinations have been developed and appear to increase lung function to a greater degree
than a LAMA alone [96]. The effect of the LABA/LAMA combination on the frequency of COPD
exacerbations is less certain because it reduced the frequency when compared with one LAMA
(i.e. glycopyrrolate) but not when compared with another LAMA (i.e. tiotropium) [96]. More studies are
needed to determine the effect of the LABA/LAMA combination on other patient-centred outcomes.
Few studies have investigated the indications and benefits of adding medications or the safety of
withdrawing medications, although one trial suggested that withdrawal of inhaled corticosteroids may not
increase the risk of moderate or severe COPD exacerbations [97]. Similarly, causes, effects and
management of nonadherence and misuse of inhalers have been scarcely studied.
We recommend:
• Therapeutic trials that analyse outcomes among different COPD subtypes, particularly those subtypes
that are at greatest risk for an undesirable outcome.
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• Therapeutic trials that compare outcomes among current smokers with former smokers.
• Therapeutic trials that evaluate outcomes using different thresholds for initiating, adding and
withdrawing medications.
• Therapeutic trials that compare outcomes among patients treated with different medications (as opposed
to placebo-controlled studies). Examples include: 1) comparisons of LAMA therapy with each type of
LABA therapy (i.e. salmeterol, formoterol, indacaterol, olodaterol and vilanterol); and 2) comparisons of
combination LAMA/LABA therapy with LABA/ICS, LAMA and LABA therapy.
• Trials comparing strategies of pharmacological treatment (e.g. treatment initiation with one single agent
and then further step-up if symptoms are not controlled versus immediate double or triple therapy).
• Studies of therapies aimed at improving cough, sputum production and dyspnoea, all of which are of
importance to patients.
• Studies assessing how pharmacological treatment complements rehabilitation programmes.
• Real-life observational studies (i.e. effectiveness studies) that assess how the results of randomised trials
(i.e. efficacy trials) may be applied to broader patient populations in usual care settings.
• Studies that determine the risk for pneumonia conferred by each formulation of the LABA/ICS
combination, as well as the aetiology and natural history of pneumonia in ICS-treated patients.
• Studies that evaluate the effects of treating common comorbidities on COPD-specific outcomes, as well
as the effects of treating COPD on outcomes specific to common comorbidities.
• Studies that identify and validate instruments that objectively determine a patient’s response to therapy.
• Studies that compare outcomes among patients managed with various strategies to improve adherence.
• Studies that compare outcomes among patients who use an inhaler with those who use a nebuliser.
• Studies of patients who are diagnosed with COPD at an early age to determine if early intervention
reduces disease progression.
Novel pharmacological therapies
Novel pharmacological therapies (i.e. anti-inflammatory therapies, long-term antibiotic therapy and
statin therapy) are discussed in the full-length version of the document, found at www.atsjournals.org and
www.erj.ersjournals.com
Managing comorbidities
Management of the rising prevalence of multiple chronic comorbidities (i.e. patients with two or more
chronic comorbidities) is a major challenge facing healthcare systems worldwide, which are dominated by
single-disease approaches [98]. In many patients, COPD should be considered to be just one component
of multiple chronic comorbidities. Generally speaking, patients with COPD and multiple chronic
comorbidities are treated according to existing standards for each individual disease. In other words,
comorbidities in patients with COPD are treated the same as in patients without COPD, and COPD is
treated the same regardless of the comorbidity. Observational studies suggest that mortality of patients
with COPD can be reduced by nonrespiratory treatments, including β-blockers, angiotensin-converting
enzyme inhibitors [99] and statins [100].
We recommend:
• Studies that evaluate the effects of treating COPD on the outcomes of comorbid diseases, as well as
studies that evaluate the effect of treating comorbid diseases on COPD-related outcomes.
Nonpharmacological therapies
Pulmonary rehabilitation
Pulmonary rehabilitation is typically provided in a hospital-based outpatient setting. Its benefits in this
setting are well established, including reduced dyspnoea, increased exercise capacity, improved quality of
life and reduced use of healthcare resources [101]. Effects on physical activity are less well studied and less
consistent. More recent research has focused on the effectiveness of pulmonary rehabilitation in alternative
settings.
Home-based pulmonary rehabilitation might improve patient-centred outcomes in a manner comparable
to hospital-based programmes, including health-related quality of life and exercise capacity [102]. A
randomised trial compared cycle ergometer exercise training in the home with the same training in a
pulmonary rehabilitation centre [103]. Dyspnoea and exercise tolerance improved to an equivalent degree
in both groups, and there were no significant safety issues in either group. However, critics have argued
that the magnitude of benefit in the hospital-based pulmonary rehabilitation group was smaller than usual,
potentially biasing the results towards no difference. This highlights the need for confirmatory studies
before concluding that home-based pulmonary rehabilitation programmes provide outcomes similar to
hospital-based programmes.
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Community-based pulmonary rehabilitation has been compared with no pulmonary rehabilitation in a
2-year randomised trial, which found that community-based pulmonary rehabilitation improved dyspnoea,
exercise endurance, strength and nutritional indices [104, 105]. The total cost of the intervention was higher
than usual care at 4 months, but this was offset at 24 months due to reduced hospital admission costs.
Pulmonary rehabilitation programmes are effective in patients after (severe) exacerbations. A systematic
review identified improvement in symptoms, health-related quality of life and exercise tolerance, as well as
possible benefits in hospital readmission rates and survival [106].
Pulmonary rehabilitation and pharmacotherapy appear to be complementary approaches to COPD care
with synergistic effects [107]. Additional details about the evidence for pulmonary rehabilitation in
patients with COPD are provided in an ATS/ERS statement on pulmonary rehabilitation [101].
We recommend:
• Studies that compare the effects of home-based pulmonary rehabilitation with hospital-based pulmonary
rehabilitation.
• Studies that compare hospital-based, home-based and community-based pulmonary rehabilitation in
different subtypes of patients with COPD, to determine which settings are most appropriate for the
various types of patients.
• Long-term studies that compare the effects of hospital-based, home-based and community-based
pulmonary rehabilitation on the maintenance of benefits. Of particular importance is evaluation of the
effects of such programmes on physical activity.
• Studies that compare the effects of various modalities, supervision protocols and programme durations
on outcomes.
• Controlled trials of early intensive rehabilitation in patients recovering from exacerbations to evaluate its
potential effect on readmission rates and other outcomes.
• Studies that evaluate strategies to maintain the benefits of pulmonary rehabilitation.
Long-term oxygen therapy
Long-term oxygen therapy (LTOT) reverses hypoxaemia. A trial that compared LTOT with no oxygen therapy
in patients with COPD with severe hypoxaemia (arterial oxygen tension (PaO2) ⩽55 mmHg) found that LTOT
improved survival [108], whereas another trial that compared oxygen administered for 19 h·day-1 with oxygen
administered for 12 h·day-1 found that the longer duration improved survival [109]. In contrast, a trial that
compared LTOT with no oxygen therapy in patients with COPD with moderate hypoxaemia
(PaO2<69 mmHg) found no effect on survival, regardless of the duration used per day [110]. This evidence has
limitations: the trials included relatively few patients and events (only 370 patients and 164 deaths, collectively),
there was a paucity of women enrolled, and two of the three trials were conducted more than 30 years ago.
These data suggest that LTOT has a mortality benefit that may be related to the severity of hypoxaemia.
Thus, LTOT is routinely prescribed for patients with severe hypoxaemia. The National Institutes of Health
has funded a trial comparing supplemental oxygen with no supplemental oxygen among patients with
mild-to-moderate hypoxaemia, the Long-term Oxygen Treatment Trial (LOTT). Among patients in the
supplemental oxygen group, those with hypoxaemia at rest will be instructed to use the supplemental
oxygen continuously, whereas those with hypoxaemia during exertion will be instructed to use the
supplemental oxygen with exertion and during sleep only.
We recommend:
• Studies that measure the effects of LTOT on outcomes in various COPD subtypes. Examples of subtypes
that warrant evaluation include patients with mild and moderate hypoxaemia, desaturation with
exertion, desaturation during sleep, comorbid heart disease, frequent exacerbations, decreased exercise
capacity or pulmonary hypertension.
• Studies that evaluate the effect of LTOT on physical activity and the relationship of this effect on other
outcomes, such as quality of life, frequency of exacerbations, and mortality.
• Studies that compare the effects of various modalities of LTOT (e.g. continuous, exercise, sleep,
combined, with or without flow titration) on outcomes in different patient subtypes.
Noninvasive mechanical ventilation
Noninvasive mechanical ventilation (NIV) improves respiratory acidosis and decreases respiratory rate,
severity of breathlessness, intubation rate, length of hospital stay and mortality in patients with COPD who
are experiencing acute on chronic respiratory failure [111–115]. Despite the success of NIV for acute
respiratory failure, the effects of long-term NIV in patients with COPD who have chronic respiratory
failure remain controversial [116, 117]. Some studies have shown benefits in health status, dyspnoea or
blood gases, but there has been little or no impact on other outcomes such as rehospitalisation rates or
mortality [118–120]. An exception is a recent study that found that NIV may improve survival in patients
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with COPD with chronic respiratory failure [121]. Uncertainty about the effects of NIV in patients with
COPD with chronic respiratory failure has led to the use of NIV on an individual basis.
We recommend:
• Studies that assess the effects of long-term NIV in patients with COPD who have chronic respiratory
failure.
• Studies that identify characteristics of patients who are most likely to benefit from long-term NIV.
Lung volume reduction surgery, lung transplantation and nutrition
Lung volume reduction surgery, lung transplantation and nutrition are discussed in the full-length version
of the document, found at www.atsjournals.org and www.erj.ersjournals.com
Integrative management, end-of-life care, pre-operative evaluation and air travel risk assessments
Integrative management, end-of-life care, pre-operative evaluation and air travel risk assessments are discussed
in the full-length version of the document, found at www.atsjournals.org and www.erj.ersjournals.com
Conclusion
COPD is a leading cause of morbidity, mortality and resource use. Strides have been made in the
identification, pathogenesis, assessment and treatment of COPD, yet many important questions remain
unanswered. This ATS/ERS research statement highlights the types of research that leading clinicians and
researchers believe will have the greatest impact on patient-centred outcomes.
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